炎症
Online ISSN : 1884-4006
Print ISSN : 0389-4290
ISSN-L : 0389-4290
トロンボキサンA2 (TxA2) のマウス実験的肝障害における意義
島沢 司青木 源典永井 博弌江田 昭英笠原 正男
著者情報
ジャーナル フリー

1989 年 9 巻 3 号 p. 201-204

詳細
抄録
Experimental liver injury models were produced by the injection of anti-basic liver protein (BLP) antibody into DBA/2 mice, by the injection of bacterial LPS into Corynebacterium parvum-pretreated ddY mice, and by the injection of CCl4 into ddY mice. In all models, extensive liver cell damage was estimated by the elevation of glutamate transaminase (GOT and GPT) activity and confirmed by significant histopathological changes of liver. Moreover, significant elevation of TxB2 in the liver was observed in all models.
Administration of OKY-046, a selective TxA2 synthetase inhibitor, ONO-3708, TxA2 receptor antagonist, and indomethacin, cyclooxygenase inhibitor, suppressed the elevation of GOT and GPT levels and histopathological changes in almost liver injury models. In addition, when U-46619, a stable TxA2 mimetic compound, was injected into mice, clear elevation of GOT and GPT was observed. These evidences suggest that TxA2 play an important role for the onset of liver injury disease in mice.
著者関連情報
© 日本炎症・再生医学会
前の記事 次の記事
feedback
Top